0001193125-26-214676
SEC filingQ1 revenue grew modestly to $22.5M driven by Contiva and Etorel sales gains, while gross profit rose to $21.3M despite higher production costs; operating and net losses widened to -$9.4M and -$9.9M from planned R&D investments and pipeline evaluation, offset by $3.2M positive operating cash flow.
Operating income declined to a $9.4 million loss from a $2.3 million profit, a -511.6% change, driven by higher operating expenses. The Company continues evaluating its pipeline and clinical development strategy, including the Cullgen acquisition, to optimize capital allocation. These planned investments in R&D and commercialization are expected to persist in the near- to medium-term, prioritizing high-potential programs. Operating margin stood at -41.5%, highlighting the trade-off between growth initiatives and near-term profitability.